Stockreport

FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma’s UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF UGN-101 Joins Select Group of Urologic Oncology Product Candidates to Receive BTD On Track to Initiate Rolling Submission of UGN-101 New Drug [Read more]